Alzheimer’s vaccine research has progressed significantly since the disease was first identified over a hundred years ago, with treatments now available that can reduce harmful proteins in the brain associated with the condition. Vaccine trials are currently underway to eliminate these proteins, with one of the most promising candidates being UB-311 developed by American company Vaxxinity. The synthetic, peptide-based immunotherapy has proved safe and tolerable in phase 2 trials and Japanese healthcare company Eisai recently developed LEQEMBI, a cost-effective vaccine for the disease.
Healthcare Cybersecurity Market Projected for Steady Growth
The global healthcare cybersecurity market is expected to reach $61.63 billion by 2031, growing at a compound annual growth rate (CAGR) of 15.5% from 2024,
